Cited by

• QT Interval Prolongation in People Treated With Bedaquiline for Drug-Resistant Tuberculosis Under Programmatic Conditions: A Retrospective Cohort Study.

  Isralls S, Baisley K, Ngam E, Grant AD, Millard J. Isralls S, et al. Open Forum Infect Dis. 2021 Aug 1;8(8):ofab413. doi: 10.1093/ofid/ofab413. eCollection 2021 Aug. Open Forum Infect Dis. 2021. PMID: 34466629 Free PMC article.
• Optimal management of drug-resistant tuberculosis: Can India lead the way?

  Masini T, Furin J, Udwadia Z, Guglielmetti L. Masini T, et al. Indian J Med Res. 2023 Feb-Mar;157(2&3):220-222. doi: 10.4103/ijmr.ijmr_300_23. Indian J Med Res. 2023. PMID: 37202941 Free PMC article. No abstract available.
• Understanding the drug exposure-response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug-resistant tuberculosis.

  Tanneau L, Karlsson MO, Svensson EM. Tanneau L, et al. Br J Clin Pharmacol. 2020 May;86(5):913-922. doi: 10.1111/bcp.14199. Epub 2020 Feb 16. Br J Clin Pharmacol. 2020. PMID: 31840278 Free PMC article.
• Integration of drug safety monitoring in tuberculosis treatment programmes: country experiences.

  Tiemersma E, van den Hof S, Dravniece G, Wares F, Molla Y, Permata Y, Lukitosari E, Quelapio M, Aung ST, Aung KM, Thuy HT, Hoa VD, Sulaimanova M, Sagyndikova S, Makhmudova M, Soliev A, Kimerling M. Tiemersma E, et al. Eur Respir Rev. 2019 Oct 11;28(153):180115. doi: 10.1183/16000617.0115-2018. Print 2019 Sep 30. Eur Respir Rev. 2019. PMID: 31604816 Free PMC article. Review.
• Compassionate drug use: Current status in India.

  Shetty YC, Brahma S, Manjesh PS. Shetty YC, et al. Perspect Clin Res. 2020 Jan-Mar;11(1):3-7. doi: 10.4103/picr.PICR_119_18. Epub 2019 Apr 26. Perspect Clin Res. 2020. PMID: 32154142 Free PMC article. Review.